1. Home
  2. WRN vs NBTX Comparison

WRN vs NBTX Comparison

Compare WRN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Copper and Gold Corporation

WRN

Western Copper and Gold Corporation

HOLD

Current Price

$2.37

Market Cap

609.2M

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$39.28

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WRN
NBTX
Founded
2006
2003
Country
Canada
France
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
609.2M
2.3B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
WRN
NBTX
Price
$2.37
$39.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$4.58
$36.00
AVG Volume (30 Days)
907.1K
150.4K
Earning Date
05-06-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$58.17
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$8.03
52 Week High
$4.26
$57.14

Technical Indicators

Market Signals
Indicator
WRN
NBTX
Relative Strength Index (RSI) 47.63 47.06
Support Level $2.28 $36.98
Resistance Level $2.54 $41.06
Average True Range (ATR) 0.09 2.80
MACD -0.01 -0.21
Stochastic Oscillator 13.22 22.76

Price Performance

Historical Comparison
WRN
NBTX

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: